Outlook Therapeutics, Inc. (NASDAQ:OTLK) Short Interest Update

Outlook Therapeutics, Inc. (NASDAQ:OTLKGet Rating) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totalling 9,680,000 shares, an increase of 48.9% from the March 15th total of 6,500,000 shares. Based on an average trading volume of 1,500,000 shares, the days-to-cover ratio is presently 6.5 days.

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Outlook Therapeutics in a report on Thursday, December 23rd.

In other news, Director Kurt J. Hilzinger acquired 95,597 shares of the stock in a transaction that occurred on Tuesday, February 22nd. The stock was purchased at an average cost of $1.49 per share, with a total value of $142,439.53. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kurt J. Hilzinger acquired 41,160 shares of the stock in a transaction that occurred on Thursday, February 24th. The stock was purchased at an average cost of $1.46 per share, with a total value of $60,093.60. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 142,757 shares of company stock worth $212,133. Insiders own 2.30% of the company’s stock.

Several large investors have recently bought and sold shares of OTLK. BlackRock Inc. grew its holdings in Outlook Therapeutics by 1.4% in the 4th quarter. BlackRock Inc. now owns 5,918,760 shares of the company’s stock worth $8,049,000 after buying an additional 80,148 shares in the last quarter. Geode Capital Management LLC grew its holdings in Outlook Therapeutics by 2.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,552,438 shares of the company’s stock worth $3,368,000 after buying an additional 36,351 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Outlook Therapeutics by 357.0% in the 4th quarter. Renaissance Technologies LLC now owns 1,164,293 shares of the company’s stock worth $1,583,000 after buying an additional 909,512 shares in the last quarter. Millennium Management LLC bought a new position in Outlook Therapeutics in the 3rd quarter worth approximately $2,084,000. Finally, Stelac Advisory Services LLC grew its holdings in Outlook Therapeutics by 39.3% in the 3rd quarter. Stelac Advisory Services LLC now owns 390,000 shares of the company’s stock worth $846,000 after buying an additional 110,000 shares in the last quarter. 11.71% of the stock is owned by institutional investors.

NASDAQ:OTLK opened at $1.82 on Friday. The stock has a 50 day moving average of $1.75 and a 200-day moving average of $1.68. Outlook Therapeutics has a 52 week low of $1.19 and a 52 week high of $3.27. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.20.

Outlook Therapeutics (NASDAQ:OTLKGet Rating) last posted its earnings results on Sunday, February 13th. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.02). As a group, sell-side analysts anticipate that Outlook Therapeutics will post -0.28 earnings per share for the current fiscal year.

Outlook Therapeutics Company Profile (Get Rating)

Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

Further Reading

Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.